This inventor holds 165 USPTO granted patents and 55 published patent applications, plus 6 CIPO patents and 83 EPO patents, primarily in Genetically Modified Mice (CPC class A01K2227-105). Top assignees: Regeneron Pharmaceuticals, Inc., Institute for Research in Biomedicine, Yale University. Active years: 2009-2026.
Inventors with similar research interests:
Location History:
- Mohegan Lake, NY (US) (2009 - 2012)
- San Diego, CA (US) (2011 - 2023)
- San Francisco, CA (US) (2012 - 2023)
- Del Mar, CA (US) (2016 - 2024)
Company Filing History:
157 out of 1,477 
23 out of 76 
22 out of 1,363 
Years Active: 2009-2026
Areas of Expertise:
Title: Sean Stevens: A Pioneer in Humanized Animal Research
Introduction:
Sean Stevens, hailing from Del Mar, CA, is a prominent figure in the field of innovation and patents. With an impressive number of 143 patents under his name, Stevens has made remarkable contributions to the scientific community. His groundbreaking research in humanized non-human animals and genetic modifications has opened new avenues for medical advancements. In this article, we explore his latest patents, career highlights, and collaborations, shedding light on his incredible contributions.
Latest Patents:
One of Stevens' most significant recent patents is titled "Humanized non-human animals with restricted immunoglobulin heavy chain loci." This patent encompasses the creation of genetically modified mice, embryos, cells, and tissues that possess a restricted immunoglobulin heavy chain locus and express one or more ADAM6 proteins. By introducing an ectopic sequence encoding ADAM6 proteins to these animals, Stevens has paved the way for studying various aspects of genetic and immunological diseases.
Another noteworthy patent by Stevens is titled "Humanized light chain mice." Through this invention, he has provided non-human animals, tissues, cells, and genetic material with modified heavy chain immunoglobulin sequences and ADAM6 activity functional in mice. These engineered animals express human immunoglobulin heavy chain variable domains along with cognate human immunoglobulin λ light chain variable domains. This breakthrough holds immense potential for advancing antibody-based therapeutic development.
Career Highlights:
With an impressive track record, Sean Stevens has worked with esteemed organizations to propel scientific advancements. He contributed significantly to Regeneron Pharmaceuticals, Inc., where his innovative research led to groundbreaking patents in the realm of humanized animal models. At Yale University, Stevens continued to make remarkable strides in genetic modification technologies, collaborating with renowned researchers and expanding the frontiers of biological research.
Collaborations:
Sean Stevens had the privilege of collaborating with experts in the field. Andrew J. Murphy, a distinguished scientist, has worked alongside Stevens, combining their expertise to advance the frontier of genetically modified animals. Additionally, Cagan Gurer, renowned for his research in immunology, has joined forces with Stevens to explore the potential applications of humanized animal models in studying immune system-related disorders.
Conclusion:
Sean Stevens stands as an influential figure in the realm of innovations and patents, particularly in the domain of genetic modifications and humanized animal models. His prolific contributions to the scientific community through his numerous patents demonstrate his dedication to advancing medical research. Stevens' collaborations with esteemed individuals have further consolidated his position as a leader in the field. His inventive work continues to inspire scientists and holds immense promise for the development of targeted therapies and treatments in the future.